Dr. Reddy’s Laboratories Ltd., India’s second-largest drugmaker, aims to be among the first three to four companies offering copies of biotechnology drugs, including a version of Roche Holding AG’s Rituxan, in Europe.
A partnership the Hyderabad-based company struck with Merck KGaA’s Merck Serono unit last year to develop cheaper copies of biologic cancer drugs could yield products in Europe in four years, Dr. Reddy’s Managing Director Satish Reddy said in an interview in Mumbai.